| 1 |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1):7-33.
|
| 2 |
Ensenyat-Mendez M, Llinàs-Arias P, Orozco J, et al. Current triple-negative breast cancer subtypes: dissecting the most aggressive form of breast cancer [J]. Front Oncol, 2021, 11:681476.
|
| 3 |
Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [J]. Ann Oncol, 2020, 31(12):1623-1649.
|
| 4 |
Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer [J]. Breast Cancer (Auckl), 2016, 10:25-36.
|
| 5 |
Vidula N, Ellisen LW, Bardia A. Novel agents for metastatic triple-negative breast cancer: finding the positive in the negative [J]. J Natl Compr Canc Netw, 2020:1-9.
|
| 6 |
Khosravi-Shahi P, Cabezón-Gutiérrez L, Custodio-Cabello S. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies [J]. Asia Pac J Clin Oncol, 2018, 14(1):32-39.
|
| 7 |
Cubas R, Li M, Chen C, et al. Trop2: a possible therapeutic target for late stage epithelial carcinomas [J]. Biochim Biophys Acta, 2009, 1796(2):309-314.
|
| 8 |
Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target [J]. Oncotarget, 2018, 9(48):28989-29006.
|
| 9 |
Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications [J]. Genes Cancer, 2015, 6(3-4):84-105.
|
| 10 |
Guerra E, Trerotola M, Aloisi AL, et al. The Trop-2 signalling network in cancer growth [J]. Oncogene, 2013, 32(12):1594-1600.
|
| 11 |
Lin H, Zhang H, Wang J, et al. A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo [J]. Int J Cancer, 2014, 134(5):1239-1249.
|
| 12 |
Cortesi M, Zanoni M, Maltoni R, et al. TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer [J]. Expert Opin Ther Targets, 2022, 26(7):593-602.
|
| 13 |
Zaman S, Jadid H, Denson AC, et al. Targeting Trop-2 in solid tumors: future prospects [J]. Onco Targets Ther, 2019, 12:1781-1790.
|
| 14 |
Zeng P, Chen MB, Zhou LN, et al. Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis [J]. Sci Rep, 2016, 6:33658.
|
| 15 |
Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth [J]. Oncogene, 2013, 32(2):222-233.
|
| 16 |
Gaber A, Kim SJ, Kaake RM, et al. EpCAM homo-oligomerization is not the basis for its role in cell-cell adhesion [J]. Sci Rep, 2018, 8(1):13269.
|
| 17 |
Ripani E, Sacchetti A, Corda D, et al. Human Trop-2 is a tumor-associated calcium signal transducer [J]. Int J Cancer, 1998, 76(5):671-676.
|
| 18 |
Tate JG, Bamford S, Jubb HC, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer [J]. Nucleic Acids Res, 2019, 47(D1):D941-D947.
|
| 19 |
Ambrogi F, Fornili M, Boracchi P, et al. Trop-2 is a determinant of breast cancer survival [J]. PLoS One, 2014, 9(5):e96993.
|
| 20 |
Lenárt S, Lenárt P, Šmarda J, et al. Trop2: Jack of All Trades, Master of None [J]. Cancers (Basel), 2020, 12(11)
|
| 21 |
Liu T, Liu Y, Bao X, et al. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway [J]. PLoS One, 2013, 8(9):e75864.
|
| 22 |
Stoyanova T, Goldstein AS, Cai H, et al. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling [J]. Genes Dev, 2012, 26(20):2271-2285.
|
| 23 |
Aslan M, Hsu EC, Garcia-Marques FJ, et al. Oncogene-mediated metabolic gene signature predicts breast cancer outcome [J]. NPJ Breast Cancer, 2021, 7(1):141.
|
| 24 |
Pak MG, Shin DH, Lee CH, et al. Significance of EpCAM and TROP2 expression in non-small cell lung cancer [J]. World J Surg Oncol, 2012, 10:53.
|
| 25 |
Hsu EC, Rice MA, Bermudez A, et al. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1 [J]. Proc Natl Acad Sci U S A, 2020, 117(4):2032-2042.
|
| 26 |
Zhao W, Jia L, Kuai X, et al. The role and molecular mechanism of Trop2 induced epithelial-mesenchymal transition through mediated β-catenin in gastric cancer [J]. Cancer Med, 2019, 8(3):1135-1147.
|
| 27 |
Lipinski M, Parks DR, Rouse RV, et al. Human trophoblast cell-surface antigens defined by monoclonal antibodies [J]. Proc Natl Acad Sci U S A, 1981, 78(8):5147-5150.
|
| 28 |
Remšík J, Binó L, Kahounová Z, et al. Trop-2 plasticity is controlled by epithelial-to-mesenchymal transition [J]. Carcinogenesis, 2018, 39(11):1411-1418.
|
| 29 |
Xie J, Mølck C, Paquet-Fifield S, et al. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells [J]. Oncotarget, 2016, 7(28):44492-44504.
|
| 30 |
Cardillo TM, Govindan SV, Sharkey RM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys [J]. Clin Cancer Res, 2011, 17(10):3157-3169.
|
| 31 |
Goldenberg DM, Cardillo TM, Govindan SV, et al. Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [J]. Oncotarget, 2020, 11(10):942.
|
| 32 |
Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase Ⅰ/Ⅱ IMMU-132-01 basket trial [J]. Ann Oncol, 2021, 32(6):746-756.
|
| 33 |
Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer [J]. N Engl J Med, 2019, 380(8):741-751.
|
| 34 |
Rugo HS, Bardia A, Marmé F, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer [J]. J Clin Oncol, 2022, 40(29):3365-3376.
|
| 35 |
Rugo HS, Bardia A, Marmé F, et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer [J]. J Clin Oncol, 2022, 40 (suppl 17): abstr LBA1001.
|
| 36 |
Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells [J]. Mol Cancer Ther, 2021, 20(12):2329-2340.
|
| 37 |
Mangino G, Grazia Capri M, Barnaba V, et al. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells [J]. Int J Cancer, 2002, 101(4):353-359.
|
| 38 |
Liu H, Bai L, Huang L, et al. Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer [J]. J Immunother Cancer, 2021, 9(10)
|
| 39 |
Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase i inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1 [J]. Clin Cancer Res, 2016, 22(20):5097-5108.
|